Introduction: disease overview and risk factors.
出版信息
P T. 2010 Mar;35(3 Section 3):2-4.
Abstract
摘要
相似文献
1
Introduction: disease overview and risk factors.
P T. 2010 Mar;35(3 Section 3):2-4.
2
Prostate cancer risk: overview of the disease, predictive factors, and potential targets for risk reduction. Introduction.
Urology. 2009 May;73(5 Suppl):S1-3. doi: 10.1016/j.urology.2009.02.021.
3
Symposium on clinical exercise testing. Introduction and overview.
Cardiol Clin. 1984 Aug;2(3):311-7.
4
Taking oral health to heart: an overview.
J Am Dent Assoc. 2002 Jun;133 Suppl:4S-6S. doi: 10.14219/jada.archive.2002.0374.
5
Postmortem aviation forensic toxicology: an overview.
J Anal Toxicol. 2010 May;34(4):169-76. doi: 10.1093/jat/34.4.169.
6
Cholesterol and cardiovascular disease: current perspectives. Introduction and overview.
Circulation. 1987 Sep;76(3):502-3. doi: 10.1161/01.cir.76.3.502.
7
Disease Risk Assessments Involving Companion Animals: an Overview for 15 Selected Pathogens Taking a European Perspective.
J Comp Pathol. 2016 Jul;155(1 Suppl 1):S75-97. doi: 10.1016/j.jcpa.2015.08.003. Epub 2015 Sep 28.
8
HIV/AIDS health worker stress and burnout: introduction and overview.
AIDS Care. 1996 Apr;8(2):133-5. doi: 10.1080/09540129650125812.
9
Cigarette smoking in the Multiple Risk Factor Intervention Trial (MRFIT). Introduction, overview, method, and conclusions.
Prev Med. 1991 Sep;20(5):552-63. doi: 10.1016/0091-7435(91)90054-8.
10
Nitrosamines and human cancer: introduction and overview.
Eur J Cancer Prev. 1996 Sep;5 Suppl 1:7-10. doi: 10.1097/00008469-199609001-00002.
本文引用的文献
1
Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
Transpl Infect Dis. 2009 Jun;11(3):195-202. doi: 10.1111/j.1399-3062.2009.00372.x. Epub 2009 Feb 18.
2
Cytomegalovirus in transplantation - challenging the status quo.
Clin Transplant. 2007 Mar-Apr;21(2):149-58. doi: 10.1111/j.1399-0012.2006.00618.x.
3
Etiology and impact of cytomegalovirus disease on solid organ transplant recipients.
Am J Health Syst Pharm. 2006 Oct 1;63(19 Suppl 5):S3-9. doi: 10.2146/ajhp060377.
4
Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.
Transplantation. 2006 Aug 15;82(3):398-405. doi: 10.1097/01.tp.0000229039.87735.76.
5
Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations.
Transplantation. 2005 Jul 27;80(2):157-63. doi: 10.1097/01.tp.0000165430.65645.4f.
6
Management of CMV infection and disease in transplant patients. 27-29 February 2004.
Herpes. 2004 Dec;11(3):77-86.
7
Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients.
Am J Health Syst Pharm. 2005 Apr 15;62(8 Suppl 1):S7-13. doi: 10.1093/ajhp/62.suppl_1.S7.
8
Prophylaxis of cytomegalovirus disease in transplant patients.
Am J Health Syst Pharm. 2005 Apr 15;62(8 Suppl 1):S3-6. doi: 10.1093/ajhp/62.suppl_1.S3.
9
Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report.
Am J Transplant. 2005 Feb;5(2):218-27. doi: 10.1111/j.1600-6143.2004.00692.x.
10
Cytomegalovirus.
Am J Transplant. 2004 Nov;4 Suppl 10:51-8. doi: 10.1111/j.1600-6135.2004.00727.x.
Zotero 插件